Meeting
2022 ASCO Annual Meeting
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Authors
Minsuk Kwon
Department of Hematology-Oncology, Ajou University, Suwon, South Korea
Minsuk Kwon , Seung Tae Kim , Jung Yong Hong , Gahyun Kim , Simon Smith , Peter G. Mortimer , Bienvenu LoembE , Emma Dean , Won Ki Kang , Jeeyun Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03780608
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4045)
DOI
10.1200/JCO.2022.40.16_suppl.4045
Abstract #
4045
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.
First Author: Minsuk Kwon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
First Author: Ning Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
First Author: Choong-kun Lee